☆ 4.6 Article

Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab

LIFE-BASEL (2023)

Related references

Note: Only part of the references are listed.

Article Otorhinolaryngology

Olfaction in nasal polyp patients after Reboot surgery: an endotype-based prospective study

Sara Costa Gomes et al.

Summary: This study investigated biomarkers in the olfactory mucosa of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and compared them with nasal polyps and nasal mucosal tissues from control patients. The study found that type-2 inflammation is present in the olfactory mucosa of CRSwNP patients and is associated with smell loss. Reboot surgery, aiming to completely remove inflamed sinus mucosa, significantly improves the smell in this group of patients.

EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY (2023)

Add to Collection

Article Allergy

Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate-to-severe type 2 asthma

Alberto Papi et al.

Summary: Dupilumab improves lung function in patients with moderate-to-severe asthma and reduces the impact of severe exacerbations on lung function.

ALLERGY (2023)

Add to Collection

Article Allergy

Immunoglobulin E and G autoantibodies against eosinophil proteins in children and adults with asthma and healthy subjects

Jorge Sánchez et al.

World Allergy Organization Journal (2023)

Add to Collection

Review Medicine, General & Internal

Pathobiology of Type 2 Inflammation in Asthma and Nasal Polyposis

Corrado Pelaia et al.

Summary: Asthma and nasal polyposis often coexist and are linked by common cellular and molecular pathways of type 2 airway inflammation. These inflammatory changes are driven by cytokines such as IL-4, IL-13, IL-5, and other proinflammatory mediators. Due to their shared pathogenesis, severe forms of both disorders can be effectively treated with biologic drugs targeting molecular components of the type 2 inflammatory trait.

JOURNAL OF CLINICAL MEDICINE (2023)

Add to Collection

Article Biochemistry & Molecular Biology

IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline

George Scott et al.

Summary: Type 2 (T2) asthma is characterized by airflow limitations and elevated levels of blood and sputum eosinophils, fractional exhaled nitric oxide, IgE, and periostin. This study aimed to determine the effect of T2 cytokines IL-4, IL-13, and IL-5 on eosinophil biology and compare the impact of depleting just eosinophils versus inhibiting all aspects of T2 inflammation on airway inflammation. The results showed that eosinophils are not the sole contributor to asthma pathophysiology or lung function decline and emphasize the need to block additional mediators to modify lung inflammation and impact lung function.

CYTOKINE (2023)

Add to Collection

Article

A real life cohort of Mepolizumab treatment in severe eosinophilic asthma

D. Laorden et al.

European Annals of Allergy and Clinical Immunology (2023)

Add to Collection

Article Critical Care Medicine

Global Initiative for Asthma Strategy 2021 Executive Summary and Rationale for Key Changes

Helen K. Reddel et al.

Summary: The article summarizes key recommendations from GINA 2021 and the recent changes, highlighting the importance of not relying solely on short-acting beta(2)-agonists for asthma treatment and provides targeted treatment suggestions based on severity and age.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2022)

Add to Collection

Article Respiratory System

European Respiratory Society guidelines for the diagnosis of asthma in adults

Renaud Louis et al.

Summary: This article discusses the challenges faced in diagnosing asthma in adults and the recommendations provided by a taskforce set up by the European Respiratory Society. The taskforce emphasizes the importance of spirometry in the initial diagnosis and suggests further tests if obstruction is not detected. They also highlight the value of phenotyping and taking into account the patient's experience in the diagnostic process.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection

Article Allergy

Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status

Shigeharu Fujieda et al.

Summary: Dupilumab consistently improved symptoms of severe CRSwNP in all ECRS subgroups, regardless of ECRS status. Blood eosinophil level may not be a suitable biomarker for dupilumab efficacy in CRSwNP.

ALLERGY (2022)

Add to Collection

Article Immunology

Regulation and directed inhibition of ECP production by human neutrophils

Antonio Vega-Rioja et al.

Summary: This study explores the molecular mechanisms underlying ECP production and investigates the effects of agonists and clinical approaches on its release. The results indicate that IgE-mediated ECP release is dependent on multiple signaling pathways, and ECP release is modulated by certain cytokines and clinical drugs. Additionally, a negative correlation between asthma severity and ECP levels was found.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Review Immunology

Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13

Corrado Pelaia et al.

Summary: Interleukin-4 (IL-4) and interleukin-13 (IL-13) play key roles in the immune-inflammatory and structural changes in type 2 asthma. Dupilumab, a fully human IgG4 monoclonal antibody, effectively inhibits type 2 inflammation by blocking the interactions between IL-4 and IL-13 with the IL-4 receptor (IL-4R alpha). This leads to reduced exacerbations, decreased use of oral corticosteroids, and lower levels of fractional exhaled NO (FeNO). Dupilumab has been approved for severe asthma, atopic dermatitis, and nasal polyposis.

VACCINES (2022)

Add to Collection

Letter Respiratory System

Eosinophilic cationic protein as marker for response to antibody therapy in severe asthma

Elisa Franceschi et al.

ERJ OPEN RESEARCH (2022)

Add to Collection

Article Otorhinolaryngology

Serum eosinophil cationic protein: a prognostic factor for early postoperative recurrence of nasal polyps

Pin-Ching Lu et al.

Summary: This study suggests that serum eosinophil cationic protein (ECP) concentration may be a feasible predictor for early postoperative recurrence of nasal polyps, with higher ECP levels associated with increased risk of early recurrence.

INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY (2021)

Add to Collection

Article Allergy

Chronic Rhinosinusitis with Nasal Polyps and Asthma

Tanya M. Laidlaw et al.

Summary: Patients with CRSwNP and asthma often have severe and recurrent disease with tissue eosinophilia and high IgE levels. The shared pathophysiology between upper and lower airways highlights the importance of systemic treatment targeting type 2 inflammatory pathways.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Letter Allergy

Prospective Italian real-world study of mepolizumab in severe eosinophilic asthma validates retrospective outcome reports

Laura Pini et al.

CLINICAL AND TRANSLATIONAL ALLERGY (2021)

Add to Collection

Article Allergy

Performance of Eosinophil Cationic Protein as a Biomarker in Asthmatic Children

Sheel N. Shah et al.

Summary: Plasma concentrations of eosinophil cationic protein (ECP) may be a useful marker of type 2 inflammation in children with asthma, helping to identify those at highest risk for exacerbations who could benefit from corticosteroid treatment. However, the sensitivity of ECP is modest and not significantly different from that of blood eosinophil counts. Additional markers may be needed to improve sensitivity for outcome detection.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Article Allergy

Mepolizumab decreased the levels of serum galectin-10 and eosinophil cationic protein in asthma

Konomi Kobayashi et al.

Summary: The study found a significant decrease in serum galectin-10 and ECP levels 4 weeks after treatment with mepolizumab. Higher ECP and eosinophil count were associated with better response in forced expiratory volume in 1 second (FEV1), suggesting ECP level as a potential predictive biomarker for the efficacy of mepolizumab.

ASIA PACIFIC ALLERGY (2021)

Add to Collection

Article Allergy

Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation

Audrey Le Floc'h et al.

ALLERGY (2020)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials

Claus Bachert et al.

LANCET (2019)

Add to Collection

Review Medicine, General & Internal

Severe Eosinophilic Asthma

Agamemnon Bakakos et al.

JOURNAL OF CLINICAL MEDICINE (2019)

Add to Collection

Article Allergy

Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis

Karin Jonstam et al.

ALLERGY (2019)

Add to Collection

Article Otorhinolaryngology

Pulmonary function in patients with eosinophilic chronic rhinosinusitis

Kensuke Uraguchi et al.

AURIS NASUS LARYNX (2018)

Add to Collection

Article Medicine, General & Internal

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma

M. Castro et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Allergy

Lower Airway Inflammation in Eosinophilic Chronic Rhinosinusitis as Determined by Exhaled Nitric Oxide

Rumi Kambara et al.

INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

J. Mark FitzGerald et al.

LANCET (2016)

Add to Collection

Article Allergy

Novel scoring system and algorithm for classifying chronic rhinosinusitis: the JESREC Study

T. Tokunaga et al.

ALLERGY (2015)

Add to Collection

Article Critical Care Medicine

Cytokines in Chronic Rhinosinusitis Role in Eosinophilia and Aspirin-exacerbated Respiratory Disease

Whitney W. Stevens et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)

Add to Collection

Review Cell Biology

Cellular Mechanisms Underlying Eosinophilic and Neutrophilic Airway Inflammation in Asthma

Girolamo Pelaia et al.

MEDIATORS OF INFLAMMATION (2015)

Add to Collection

Review Biochemistry & Molecular Biology

Eosinophil Granule Proteins: Form and Function

K. Ravi Acharya et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2014)

Add to Collection

Article Allergy

Eosinophil peroxidase in sputum represents a unique biomarker of airway eosinophilia

P. Nair et al.

ALLERGY (2013)

Add to Collection

Article Allergy

Serum eosinophil granule proteins predict asthma risk in allergic rhinitis

L. P. Nielsen et al.

ALLERGY (2009)

Add to Collection

Article Allergy

Development of the asthma control test: A survey for assessing asthma control

RA Nathan et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)

Add to Collection

© Peeref 2019-2024. All rights reserved.